# Pediatric Vaccine Safety Assessment

## INPUT

**Attach the PDF file to be analyzed along with this prompt** (package insert, clinical study article, or similar)

---

## Objective

Evaluate the safety evidence for children (0-12 years) in the attached document, answering the central question:

> **"Does this document give me confidence that this vaccine is safe for my child ‚Äî now and in the future?"**

---

## Evaluation Criteria

### 1. Pediatric sample size

How many children were studied? Small samples cannot detect rare events (1 in 1,000, 1 in 10,000).
**Ideal:** >3,000 children per age group.

### 2. Follow-up duration

How long were children monitored after vaccination? Autoimmune and neurological problems may take months or years to appear.
**Ideal:** Minimum 12 months; 2-3+ years to assess long-term effects.

### 3. Comparison group

How do we know an event was caused by the vaccine and not coincidence? There must be a group that did not receive the vaccine for comparison.
**Ideal:** True placebo (saline solution), with random allocation (randomization) and double-blind (neither parents nor doctors knew who received what).

### 4. Active surveillance for serious events

Did researchers actively look for serious problems or just wait for someone to report them?
**Ideal:** Regular contact with families, review of medical records, investigation of any hospitalization/death/sequela with causality analysis.

### 5. Neurological/developmental monitoring

Did they check if children developed normally months and years later? Did they assess seizures, delays, autoimmune conditions?
**Ideal:** Scheduled developmental assessments, follow-up neurological exams, active surveillance for conditions such as Guillain-Barr√©, seizures, skill regression.

### 6. Vulnerable subgroups

Was it tested in children with special conditions? Premature and immunosuppressed children may react differently.
**Ideal:** These groups were intentionally included and their results are presented separately.

### 7. Data transparency

Is it possible to verify the complete study data, or is only a summary available?
**Ideal:** Publication in a peer-reviewed journal with complete data on all adverse events, or raw data available for independent analysis.

### 8. Post-marketing surveillance

What was discovered after millions of children received it? Is there ongoing monitoring?
**Ideal:** Active pharmacovigilance system mentioned, with periodic public reports and new safety signals identified.

---

## Rating Scale

|Symbol|Level         |Meaning                                              |
|------|--------------|-----------------------------------------------------|
|‚≠ê    |Excellent     |Strong and reassuring evidence on this point         |
|‚úÖ    |Adequate      |Addressed reasonably                                 |
|‚ö†Ô∏è    |Partial       |Mentioned, but with flaws or incomplete information  |
|üî¥    |Insufficient  |Mentioned, but too limited to provide confidence     |
|‚ùì    |No information|Does not provide information on this point           |

---

## Evaluation Rules

1. Base your assessment **only** on the attached document ‚Äî do not assume something was done if it is not written
1. If not mentioned, classify as ‚ùì
1. When in doubt between two levels, choose the more conservative one
1. Be specific: cite numbers and durations when available

---

## Output Format

### TABLE

|Criterion                         |Rating|
|----------------------------------|------|
|Pediatric sample size             |      |
|Follow-up duration                |      |
|Comparison group                  |      |
|Active surveillance for serious events|  |
|Neurological/developmental monitoring|   |
|Vulnerable subgroups              |      |
|Data transparency                 |      |
|Post-marketing surveillance       |      |

**Format for the "Rating" column:** Emoji + level + brief explanation.

Example:

> ‚ö†Ô∏è **Partial** ‚Äî Only 6 months of follow-up; insufficient to detect long-term effects.

### SUMMARY

A single paragraph starting with **emoji + overall rating**, followed by an honest and direct assessment of what this document proves (or does not prove) about the safety of this vaccine in children.
